-

Shareholder Alert: Robbins LLP Announces the Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss

SAN DIEGO & NEWTON, Mass.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc. (NASDAQ: ACER) may face damages caused by a pending securities class action. Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for rare and life-threatening diseases.

If you suffered a loss as a result of Acer's misconduct, click here.

Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss

According to the complaint, Acer misrepresented that a conversation it had with the U.S. Food and Drug Administration regarding its drug candidate EDVISO. Acer claimed publicly that "the FDA agreed that additional clinical development is not needed" for the drug. Acer went on to raise almost $59 million in two offerings based on this information. However, contrary to Acer's public comments, the FDA had not approved the new drug application for EDVISO. In June 2019, when Acer revealed that the FDA needed it to "conduct an adequate and well-controlled trial" to determine EDVISO's effects in patients, Acer's stock price fell $15.16 per share, or over 75%, to close at $4.12 per share. On June 16, 2020, U.S. District Court Judge Gregory H. Woods denied in part Acer's motion to dismiss plaintiffs' claims, stating that plaintiffs had plausibly alleged securities fraud claims. On July 21, 202, Judge Woods subsequently denied Defendants' motion to reconsider his decision, paving the way for litigation to proceed.

Acer Therapeutics Inc. (ACER) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Acer settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Reminds Primo Brands Corporation Stockholders on the January 12, 2026 Lead Plaintiff Deadline – Contact us today for information about the PRMB class action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Primo Brands Corporation (NYSE: PRMB) purports to be a leading North American branded beverage company focused on healthy hydration, offering responsibly sourced products across multiple formats, channels, and price points, and for a wide range of consumer occasions. Its products are distributed in every U.S. state and in Canada. Who is part of the class? The case purportedly represents stockholders who purchased or otherwise acquired (i) the co...

Robbins LLP Reminds Telix Pharmaceuticals Ltd. Stockholders About the January 9, 2026 Lead Plaintiff Deadline – Contact Us Today for Information About the TLX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. What is the class period? February 21, 2025 - August 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or acquired Telix securities during the class peri...

Robbins LLP Reminds Freeport-McMoran Inc. Stockholders of the January 12, 2026 Lead Plaintiff Deadline – Contact us today for information about the FCX class action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Freeport-McMoran Inc. (NYSE: FCX) is a mining company. What is the class period? February 15, 2022 - September 24, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Freeport during the class period because the Company allegedly misled investors regarding safety at its mines. For more information, submit a form, email attorney Aaron Dumas, Jr....
Back to Newsroom